Muhammad Waleed Asfandyar, Akhtar Ahmed, Naureen Nizar, Altaf Hashmi, Anwar Naqvi and Syed Adib-ul-Hasan Rizvi
Sindh Institute of Urology and Transplantation, Pakistan
Posters & Accepted Abstracts: J Cancer Sci Ther
Aim: To evaluate the ability of serum PSA between 2 cutting points considering it as a predictor of bone metastases on bone scan in prostate cancer. Materials & Methods: From Aug to Nov-2013, 42 patients with prostate cancer who underwent bone scan were analyzed. All patients necessarily have a pathological report available. Bony metastases were determined from the bone scan studies and no further correlation with histopathology or other imaging modalities were performed. Results: The mean age, mean PSA and incidence of bone metastasis on bone scan were 68.35 years, 370.51 ng/mL and 19/42 (45.23%), respectively. According to PSA levels, patients were divided into 5 groups <10ng/mL (10/42), 10-20 ng/mL (5/42), 20-50 ng/mL (2/42), 50-100 (3/42), 100-500ng/mL (3/42) and more than 500ng/mL (0/42) presenting negative bone scan. The incidence of positive bone scan (%) for bone metastasis for each group were 01 patient (5.26%), 0%, 03 patients (15.78%), 01 patient (5.26%), 04 patients (21.05%), and 10 patients (52.63%), respectively. Therefore, when the cutting point adopted for PSA serum concentration was 10 ng/mL, a negative predictive value (NPV) for bone metastasis was 95% with sensitivity rates 94.74%; and the PPV and specificity of the method were 56.53% and 43.48%, respectively. When the cutting point of PSA serum concentration was 20 ng/mL the observed results for PPV and specificity were 78.27% and 65.22% respectively, whereas NPV and sensitivity stood 100% and 95% respectively. Conclusion: We concluded that serum PSA concentration of higher than 20 ng/mL was the more accurate cutting point than a serum concentration of PSA higher than 10 ng/mL to predict metastasis on bone scan.
Email: waleed_siut@yahoo.com
Cancer Science & Therapy received 3968 citations as per Google Scholar report